Important notice: Alluvi has never operated any social media accounts. Any profile using the Alluvi name is a scam. Alluviretatrutide.uk is the only official Alluvi website.Important notice: Alluvi has never operated any social media accounts. Any profile using the Alluvi name is a scam. Alluviretatrutide.uk is the only official Alluvi website.Important notice: Alluvi has never operated any social media accounts. Any profile using the Alluvi name is a scam. Alluviretatrutide.uk is the only official Alluvi website.
ALLUVI

Home » Shop » Retatrutide 40mg (R&D Only)

Retatrutide 40mg (R&D Only)
← Back to Shop

Retatrutide 40mg

R&D Only

£179.99

8 week supply
Higher concentration Retatrutide formulation for extended research protocols.

Delivery: Dispatched with a cold pack.
  • Higher concentration formulation
  • Pre-filled pen system
  • 8-week research supply
  • Cold chain logistics
  • Research & Development purposes only

Research & Development purposes only. Not for human or veterinary consumption.

Certificate of Analysis

Batch-tested quality assurance for research-grade material

Certificate of Analysis - Retatrutide 40mg

Quality Assurance Report

ProductRetatrutide 40mg (R&D Only)
Batch NumberRT-2402-B
Certificate IDRT-2402-C3914
Test DateJune 2026
Purity (HPLC)PASS
Identity (ESI-MS)PASS
EndotoxinPASS
StatusAPPROVED FOR RESEARCH USE
Verification: This certificate applies to batch RT-2402-B only. Each batch is independently tested using HPLC, ESI-MS, and USP methods.
Storage: -20°C. For research and development purposes only. Not for human or veterinary use.
Download Full Report (PDF)

Scientific References

  1. Jastreboff AM, Kaplan LM, Frías JP, et al. "Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial." N Engl J Med. 2023;389:514–526. PubMed
  2. Rosenstock J, Frias J, Jastreboff AM, et al. "Retatrutide, a GIP/GLP-1/Glucagon Receptor Agonist, for Type 2 Diabetes — A Phase 2 Study." N Engl J Med. 2023;389:1191–1203. PubMed
  3. Retatrutide — Wikipedia. Encyclopedia entry covering pharmacology, clinical trial data, and mechanism of action for this GIP/GLP-1/glucagon triple receptor agonist.

These references are provided for informational and research reference purposes. Alluvi does not claim that its products reproduce the results of cited studies. Products are supplied exclusively for controlled research and development purposes.